X
[{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ascendis Pharma A\/S to Host Virtual R&D Program Update on December 14","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dose Escalation Data From TranscendIT-101, Ascendis Pharma\u2019s Phase 1\/2 Trial of TransCon\u2122 TLR7\/8 Agonist in Patients with Advanced Solid Tumors, Presented at SITC 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"SURGE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SURGE Therapeutics Receives FDA Clearance of IND Application to Initiate Phase 1\/2a Study of Intraoperative Immunotherapy in Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals for Resiquimod
Filters
Companies By Therapeutic Area
Details:
STM-416 (Resiquimod), is a TLR7 and TLR8 agonist which is being invstigated for prevention of recurrence or progression after transurethral resection of bladder tumor (TURBT) in patients with non-muscle invasive bladder cancer (NMIBC)
Lead Product(s):
Resiquimod
Therapeutic Area: Oncology
Product Name: STM-416
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 04, 2023
Details:
TransCon TLR7/8 Agonist is an investigational long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (TLR) 7 and 8 designed to provide sustained activation of intratumoral antigen-presenting cells driving tumor antigen presentation.
Lead Product(s):
Resiquimod ,Pembrolizumab
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 11, 2022
Details:
Resiquimod, a small molecule agonist of Toll-like receptors, is designed to provide sustained activation of intratumoral antigen presenting cells driving tumor antigen presentation and induction of immune stimulatory cytokines in the tumor.
Lead Product(s):
Resiquimod
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 07, 2021